DSM Venturing Invests In Tianjin GreenBio
This article was originally published in PharmAsia News
Executive Summary
Holland DSM Venturing has completed its initial investment in China that involves a $20 million share in Tianjin Green Biosciences Ltd. Co. The fund will be used to build China's largest polyhydroxyalkanoate production in Tianjin Economic - Technological Development Area, with construction to begin in the second quarter of this year. Targeted for operation in the beginning of 2009, the facility has the capacity to output 10,000 tonnes of PHA annually. DSM chose to invest in PHA for its use in the production of environment-friendly products. The company revealed that it has allocated €200 million for venture capital before 2012 and China will be one of its key investment areas. (Click here for more - Chinese Language)
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.